인도의 혈관 접근 기기시장 규모는 2026-2033년의 예측 기간 동안 6.81%의 연평균 복합 성장률(CAGR)로 확대되어 2025년 4억 7,993만 달러에서 2033년 7억 6,107만 달러로 성장할 것으로 예상됩니다. 인도의 혈관 접근 기기시장은 장기적인 혈관 접근을 필요로 하는 당뇨병, 암과 같은 생활습관병이 증가함에 따라 크게 성장하고 있습니다. 병원 인프라에 대한 정부의 투자와 의료 서비스에 대한 접근성 향상으로 기기 채택이 가속화되고 있습니다. 또한, 카테터의 소재와 디자인 혁신은 안전성, 효율성, 환자 결과를 개선하여 의료 환경 전반에 걸쳐 카테터의 보급을 더욱 촉진하고 있습니다.
예를 들어, Abbott는 인도에서 Ultreon 1.0 소프트웨어를 통한 새로운 혈관 영상 플랫폼 도입을 선언했습니다. 인공지능(AI)과 광간섭단층촬영(OCT)을 이용한 혈관 내 영상 소프트웨어는 의사가 관상동맥의 막힘과 혈류를 철저히 파악할 수 있도록 도와줍니다. 이 최첨단 영상 소프트웨어는 혈관의 직경을 평가하고, 칼슘에 의한 막힘 정도를 파악하며, 석회화된 막힘과 그렇지 않은 막힘을 자동으로 구분할 수 있습니다. 관상동맥 스텐트 삽입술의 정확성을 향상시키기 위해 스텐트 삽입을 정확하게 안내하고, 최적의 스텐트 확장 및 삽입을 보장하며, 결과를 즉각적으로 표시합니다.
인도의 혈관 접근 기기(Vascular Access Device) 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 용도별, 최종사용자별, 지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.
India vascular access devices market is projected to witness a CAGR of 6.81% during the forecast period FY2026-FY2033, growing from USD 479.93 million in FY2025 to USD 761.07 million in FY2033. India market for vascular access devices has grown significantly because of the rising prevalence of lifestyle-related diseases such as diabetes and cancer, which require long-term vascular access. Government investments in hospital infrastructure and improved access to healthcare services are accelerating device adoption. Additionally, innovation in catheter materials and design is enhancing safety, efficiency, and patient outcomes, promoting further uptake across healthcare settings.
For example, Abbott declared the introduction of their new vascular imaging platform in India, which is driven by Ultreon 1.0 software. Using artificial intelligence (AI) and optical coherence tomography (OCT), intravascular imaging software gives doctors a thorough understanding of coronary artery blockages and blood flow. The cutting-edge imaging software can assess vessel diameter, identify the degree of calcium-based blockages, and automatically distinguish between calcified and non-calcified blockages. In order to improve accuracy during coronary stenting procedures, it also assists doctors in guiding exact stent deployment, guaranteeing optimal stent expansion and apposition with instantaneous results presentation.
Growing Burden of Chronic and Infectious Diseases in India
India is witnessing a steep rise in the prevalence of chronic diseases such as cancer, chronic kidney disease, and cardiovascular ailments, along with infections requiring frequent hospitalizations. These conditions often demand long-term administration of medications, IV fluids, and blood transfusions, significantly increasing the demand for vascular access devices. Additionally, the increasing geriatric population, which is more susceptible to chronic conditions, has contributed to higher hospitalization and intravenous intervention rates. Moreover, the burden of infectious diseases like dengue and sepsis continues to require efficient diagnostic and treatment solutions, further supporting the need for secure vascular access. Government schemes such as Ayushman Bharat and expanded healthcare coverage are improving access to healthcare facilities, which in turn increases procedural volumes where vascular access devices are used. This broad healthcare push, combined with higher patient volumes and increasing disease burden, is driving consistent growth in the demand for vascular access devices across India. The burden of noncommunicable diseases (NCDs) has overtaken that of infectious diseases in India. An estimated 5.8 million Indians lose their lives to NCDs annually, and one in four Indians are at danger of passing away before turning 70. The World Health Organization (WHO) estimates that NCDs cause nine million deaths a year in Southeast Asia, or 62% of all deaths. The high rate of premature fatalities, or deaths that happen before the age of 70, associated with NCDs is a serious concern.
Rising Healthcare Infrastructure and Technological Advancements
India's healthcare infrastructure has seen massive development in recent years, with increasing numbers of public and private hospitals, specialty clinics, and diagnostic centers. These facilities are increasingly adopting advanced medical devices, including next-generation vascular access devices that offer safer insertions, longer dwell times, and improved infection control. Local manufacturing by Indian companies such as Poly Medicure and Newtech Medical Devices has led to the availability of cost-effective, technologically enhanced solutions that match global standards. Additionally, the "Make in India" initiative has catalyzed innovation and local production of vascular access devices, enhancing availability and affordability. Hospitals and surgical centers are becoming more equipped with imaging-guided insertion tools, antimicrobial-coated catheters, and closed IV systems to reduce complications. This rapid evolution in infrastructure, alongside the acceptance of new technologies in vascular access, is playing a pivotal role in strengthening the market across Tier 1 and Tier 2 cities in India. In August 2023, Poly Medicure Ltd., a major Indian vascular access device manufacturer, opened its 10th manufacturing facility in India to enhance its product offerings, including central venous catheters, PICCs, and other vascular access solutions, under the "Make in India" initiative. This expansion supports the local availability of advanced and affordable vascular access devices.
High Adoption of Central Vascular Access Devices in Critical Care
Central vascular access devices (CVADs) are witnessing increasing demand in India, especially in ICUs and oncology centers. Their ability to provide long-term venous access, administer large volumes of fluids, chemotherapeutics, and parenteral nutrition makes them critical for managing severely ill patients. In tertiary care hospitals, CVADs are preferred for hemodynamic monitoring and blood sampling in patients requiring prolonged treatment. Moreover, the rising number of organ transplants, dialysis cases, and cancer treatments are expanding their use. Central lines, such as peripherally inserted central catheters (PICCs), tunneled catheters, and implanted ports, are gaining traction due to their lower infection rates and enhanced patient comfort when used for long durations. The increasing awareness about catheter-associated bloodstream infections (CLABSIs) is also encouraging hospitals to adopt high-quality CVADs with antimicrobial coatings. This growing preference and usage in critical care and oncology settings are making central vascular access devices a key revenue-generating segment in the Indian market. In March 2024, AIIMS Delhi announced upgrades to its ICU facilities, including the adoption of new generation of antimicrobial-coated central venous catheters (CVCs) for critical care, aimed at reducing bloodstream infections. This is part of their infection control program and reflects a growing preference for central vascular access devices in tertiary and teaching hospitals.
Future Market Scenario (FY2026 - FY2033F)
The India vascular access devices market is expected to witness robust growth in the coming years, driven by increasing hospital admissions, a rising burden of chronic diseases, and expanding healthcare infrastructure. With growing awareness of infection control and a push for safer, more efficient intravenous access methods, demand for advanced vascular access technologies is projected to rise. Additionally, government initiatives to strengthen public healthcare facilities and the rise of private multispecialty hospitals are anticipated to support market expansion. Local manufacturing capabilities and technological collaborations may further enhance the domestic supply chain for these devices.
Key Players Landscape and Outlook
Key players in the vascular access devices industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, former L&T chairman AM Naik and seasoned businessman Madhusudan Kela are among the investors who have contributed approximately Rs 300 crore to S3V Vascular Technologies Limited, a medical device manufacturing company situated in Mysore.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.